Translational researchers from UCLA’s Jonsson Comprehensive Cancer Center have published results of two back-to-back studies in the journal Cancer Discovery that provide critical insights into two key areas of how tumors resist BRAF inhibitors: the key cell-signaling pathways BRAF-mutant melanoma cells use to learn how to become resistant to inhibitor drugs, and how the limited focus of BRAF inhibitors allows melanoma cells to evolve and develop drug resistance. Read more here.
Study mentioned: Shi H, et al. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discov. 2013 Nov 21. [Epub ahead of print] PMID: 24265155
Study mentioned: Shi H, et al. A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discov. 2013 Nov 21. [Epub ahead of print] PMID: 24265152
No comments:
Post a Comment